An Introduction to Gout
Gout, the most common inflammatory arthritis worldwide, is characterized by intense pain and impaired quality of life. Management strategies include weight management, increasing exercise and reducing alcohol consumption to reduce uric acid levels, as well as treatment with xanthine oxidase inhibitors. Other urate-lowering strategies include the selective uric acid reabsorption inhibitors lesinurad and arhalofenate. An acute attack of gout is likely to require treatment with a nonsteroidal anti-inflammatory drug (NSAID) or colchicine. Emerging anti-inflammatory strategies involving targeted anti-interleukin (IL) therapy appear effective in reducing the pain of acute attacks as well as preventing recurrent attacks.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Robert Terkeltaub, ACR 2021: Tigulixostat for the Treatment of Gout with Hyperuricemia
It was a pleasure to meet with Professor Robert Terkeltaub (UC San Diego, San Diego, California, USA) to discuss the efficacy and safety findings from the phase 2 study of tigulixostat in gout with hyperuricemia (NCT03934099). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, […]
Thomas MacDonald, ACR 2020 – Cardiovascular Safety of Febuxostat and Allopurinol in Chronic Gout: The FAST Study (Part 2)
In Part 2, Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) discusses further how the results of the FAST study compared to another study, the CARES trial, which also investigated the cardiovascular risks associated with these two treatments. The late-breaking abstract entitled ‘Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: […]
Thomas MacDonald, ACR 2020 – Cardiovascular safety of Febuxostat and Allopurinol in Chronic Gout: The FAST Study (Part 1)
Following concerns related to the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. Here we talk to Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) about the results of this study and what they mean. The late-breaking abstract entitled ‘Long Term Cardiovascular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!